Latest Headlines

Latest Headlines

High court dashes Actelion's hopes for $407M reprieve in Tracleer case

Actelion has lost its fight against a $407 million court judgment. California's Supreme Court rebuffed the Swiss drugmaker's appeal in a lawsuit over competition for its top-selling drug, the pulmonary arterial hypertension (PAH) treatment Tracleer. That affirms a lower court's ruling that Actelion intentionally thwarted a rival by acquiring a drug company and then spiking its prospective Tracleer competitor.

Actelion's diarrhea drug hops on the FDA fast track

The FDA has granted its fast-track status to Actelion's Phase III drug for C. difficile-related diarrhea, promising a shorter path to approval for the antibiotic treatment.

Aggressive Gilead considers head-to-head PAH showdown with Actelion

In an interview with Bloomberg, COO John Milligan says the big biotech outfit--which is expected to generate megablockbuster revenue from the newly approved Sovaldi for hep C--is pondering a head-to-head study to determine whether Letairis is better or worse than Actelion's recently approved lung drug Opsumit.

Actelion gets second boost for Opsumit with EU approval

The Swiss drugmaker said in a statement that the EC approved the drug for use by itself or in concert with another PAH drug. Actelion intends to begin selling it in Europe in February, with Germany first in line to get it.

Actelion will pay $407M in damages for its buyout to protect Tracleer

Drugmakers have often been accused of trying to thwart competition with arrangements like pay-for-delay deals or aggressive patent litigation to protect their key drugs. But Swiss drugmaker Actelion went even further than that, a court ruled, buying out a drug company and then canceling a development deal in an effort to protect its only significant product at the time, PAH drug Tracleer.

With Opsumit approved, analysts say Actelion primed for takeover

The EU on Friday recommended approval of Actelion's Opsumit, following FDA approval the week before, and by today the takeover talk was in full swing. With regulators giving thumbs up to a drug projected to be a blockbuster, analysts say any number of companies may want to do a deal and add the assured revenue to their own top lines.

UPDATED: Actelion gets FDA approval for Opsumit, follow-up PAH drug to its Tracleer

Actelion has been anxiously awaiting FDA approval of its new pulmonary arterial hypertension treatment Opsumit, a follow-up to its only significant product, Tracleer, which goes off patent in 2015. Friday it got it.

UPDATED: Actelion wins crucial FDA approval for next-gen lung disease drug Opsumit

Late on Friday the FDA came through with an approval for Actelion's pulmonary arterial hypertension drug Opsumit (macitentan), its next-gen successor to the franchise drug Tracleer.

Q3 earnings: Abbott ups dividend, Actelion confirms growth, Baxter hurt by merger costs

In its third-quarter earnings  report, Abbott surprised investors with a sizable dividend boost, while Actelion assured shareholders it can deliver new profit streams before blockbuster Tracleer goes off patent in 2015. Baxter's report was a little less rosy, with earnings falling on acquisition costs.

Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel

Ceptaris Therapeutics won FDA approval for its topical treatment for mycosis fungoides, the most common form of cutaneous T-cell lymphoma. The gel delivers the chemotherapeutic agent mechlorethamine, previously only approved for intravenous treatment.